exitop 25 mg kapsel, mjuk
baxter medical ab - etoposid - kapsel, mjuk - 25 mg - propylparahydroxibensoat hjälpämne; etylparahydroxibensoat hjälpämne; sorbitol hjälpämne; etoposid 25 mg aktiv substans; glycerol hjälpämne - etoposid
exitop 50 mg kapsel, mjuk
baxter medical ab - etoposid - kapsel, mjuk - 50 mg - propylparahydroxibensoat hjälpämne; etylparahydroxibensoat hjälpämne; sorbitol hjälpämne; etoposid 50 mg aktiv substans; glycerol hjälpämne - etoposid
tecentriq
roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastiska medel - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq som monoterapi är indicerat för behandling av vuxna patienter med lokalt avancerad eller metastaserad icke-småcellig lungcancer efter tidigare kemoterapi. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq som monoterapi är indicerat för behandling av vuxna patienter med lokalt avancerad eller metastaserad icke-småcellig lungcancer efter tidigare kemoterapi. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.
imfinzi
astrazeneca ab - durvalumab - carcinom, non-small cell lung - antineoplastiska medel - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).
kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - andra antineoplastiska medel - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
wellvone 150 mg/ml oral suspension
glaxosmithkline ab - atovakvon - oral suspension - 150 mg/ml - bensylalkohol hjälpämne; atovakvon 150 mg aktiv substans - atovakvon
malarone 250 mg/100 mg filmdragerad tablett
glaxosmithkline ab - atovakvon; proguanilhydroklorid - filmdragerad tablett - 250 mg/100 mg - proguanilhydroklorid 100 mg aktiv substans; atovakvon 250 mg aktiv substans - kombinationer
provaqomyl 250 mg/100 mg filmdragerad tablett
viatris limited - atovakvon; proguanilhydroklorid - filmdragerad tablett - 250 mg/100 mg - laktosmonohydrat hjälpämne; proguanilhydroklorid 100 mg aktiv substans; atovakvon 250 mg aktiv substans - kombinationer
malastad 250 mg/100 mg filmdragerad tablett
stada arzneimittel ag - atovakvon; proguanilhydroklorid - filmdragerad tablett - 250 mg/100 mg - atovakvon 250 mg aktiv substans; proguanilhydroklorid 100 mg aktiv substans - kombinationer
atovaquone/proguanil orifarm 250 mg/100 mg filmdragerad tablett
orifarm generics a/s - atovakvon; proguanilhydroklorid - filmdragerad tablett - 250 mg/100 mg - atovakvon 250 mg aktiv substans; proguanilhydroklorid 100 mg aktiv substans - kombinationer